ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse

Completed · Phase 2

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of glioblastoma multiforme. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have glioblastoma multiforme in first relapse.

Key facts

Study ID

NCT00016991

Run by

Duke University

Starts

2001-06-01

Expected to finish

2005-04-01

Last updated by the study team

2013-06-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Duke Comprehensive Cancer Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.